Pathophysiology, evaluation, and treatment of bloating: Hope, hype, or hot air?

Gastroenterology and Hepatology

Volumn 7, Issue 11, 2011, Pages 729-739

  Lacy, Brian E ^a,b   Gabbard, Scott L ^b   Crowell, Michael D ^c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Abdominal distention; Abdominal pain; Antibiotics; Bloating; Fiber; Fructose; Irritable bowel syndrome

Indexed keywords

ALPHA GALACTOSIDASE; ANTIBIOTIC AGENT; CHARCOAL; CISAPRIDE; CYANOCOBALAMIN; DESIPRAMINE; DOMPERIDONE; LINACLOTIDE; LUBIPROSTONE; MACROGOL; MEBEVERINE; METOCLOPRAMIDE; NEOSTIGMINE; OTILONIUM BROMIDE; PROBIOTIC AGENT; PRUCALOPRIDE; PYRIDOSTIGMINE; RIFAXIMIN; SIMETHICONE; SUCAMPO; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE; UNCLASSIFIED DRUG; VITAMIN D;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABDOMINAL REFLEX; ANTIBIOTIC THERAPY; BACTERIAL OVERGROWTH; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM LONGUM INFANTIS; BLOATING; BODY POSTURE; BREATH ANALYSIS; COLONY FORMING UNIT; CONSTIPATION; DIAPHRAGM MOVEMENT; DIARRHEA; DIETARY INTAKE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENDOSCOPY; EXERCISE; GAS; HUMAN; INTESTINE FLORA; INTESTINE GAS; INTESTINE INFECTION; INTESTINE TRANSIT TIME; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; NAUSEA; PATHOPHYSIOLOGY; PERCEPTION DISORDER; PNEUMATOSIS INTESTINALIS; PSEUDOMEMBRANOUS COLITIS; PSYCHOSOCIAL DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMALL INTESTINE BACTERIAL OVERGROWTH; STOMACH PARESIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 84855714544     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569-1580. (Pubitemid 23271409)
2. Lembo T, Naliboff B, Munakata J, et al. Symptoms and visceral perceptions in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol. 1999;94:1320-1326. (Pubitemid 29214648)
3. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491.
4. Lewis MJ, Reilly B, Houghton LA, Whorwell PJ. Ambulatory abdominal inductance plethysmography: towards objective assessment of abdominal distention in irritable bowel syndrome. Gut. 2001;48:216-220. (Pubitemid 32141846)
5. Lea R, Reilly B, Whorwell PJ, Houghton LA. Abdominal bloating in the absence of physical distension is related to increased visceral hypersensitivity [abstract]. Gastroenterology. 2004;126:432.
6. Houghton LA, Lea R, Agrawal A, Reilly B, Whorwell PJ. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology. 2006;131:1003-1010. (Pubitemid 44498692)
7. Sandler RS, Stewart WF, Liberman JN, Ricci JA, Zorich NL. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci. 2000;45:1166-1171. (Pubitemid 30409462)
8. Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7:68-72.
9. Jiang X, Locke GR 3rd, Choung RS, Zinsmeister AR, Schleck CD, Talley NJ. Prevalence and risk factors for abdominal bloating and visible distention: a population-based study. Gut. 2008;57:756-763. (Pubitemid 351716967)
10. Ho KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am J Gastroenterol. 1998;93:1816-1822. (Pubitemid 29071687)
11. Heitkemper MM, Cain KC, Jarrett ME, Burr RL, Crowell MD, Woods NF. Relationship of bloating to other GI and menstrual symptoms in women with irritable bowel syndrome. Dig Dis Sci. 2004;49:88-95. (Pubitemid 38183751)
12. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43:541-550.
13. Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol. 2008;103:2536-2543.
14. Kindt S, Van Oudenhove L, Mispelon L, Caenepeel P, Arts J, Tack J. Longitudinal and cross-sectional factors associated with long-term clinical course in functional dyspepsia: a 5-year follow-up study. Am J Gastroenterol. 2011;106:340-348.
15. Crowell MD, Cheskin LJ, Musial F. Prevalence of gastrointestinal symptoms in obese and normal weight binge eaters. Am J Gastroenterol. 1994;89:387-391. (Pubitemid 24074400)
16. Chami TN, Andersen AE, Crowell MD, Schuster MM, Whitehead WE. Gastrointestinal symptoms in bulimia nervosa: effects of treatment. Am J Gastroenterol. 1995;90:88-92.
17. Hart AI, Stagg AJ, Groffner H, et al. Gut Ecology. London, United Kingdom: Martin Duntiz Ltd; 2002.
18. Levitt MD. Volume and composition of human intestinal gas determined by means of an intestinal washout technic. N Engl J Med. 1971;284:1394-1398.
19. Lasser RB, Bond JH, Levitt MD. The role of intestinal gas in functional abdominal pain. N Engl J Med. 1975;293:524-526.
20. Perez F, Accarino A, Azpiroz F, Quiroga S, Malagelada JR. Gas distribution within the human gut: effect of meals. Am J Gastroenterol. 2007;102:842-849. (Pubitemid 46496614)
21. Serra J, Azpiroz F, Malagelada JR. Gastric distension and duodenal lipid infusion modulate intestinal gas transit and tolerance in humans. Am J Gastroenterol. 2002;97:2225-2230.
22. Harder H, Serra J, Azpiroz F, Malagelada JR. Reflex control of intestinal gas dynamics and tolerance in humans. Am J Physiol Gastrointest Liver Physiol. 2004;286:G89-G94. (Pubitemid 38055841)
23. Serra J, Salvioli B, Azpiroz F, Malagelada JR. Lipid-induced intestinal gas retention in irritable bowel syndrome. Gastroenterology. 2002;123:700-706. (Pubitemid 34977075)
24. Hernando-Harder AC, Serra J, Azpiroz F, Malagelada JR. Sites of symptomatic gas retention during intestinal lipid perfusion in healthy subjects. Gut. 2004;53:661-665. (Pubitemid 38561443)
25. Tomlin J, Lowis C, Read NW. Investigation of normal flatus production in healthy volunteers. Gut. 1991;32:665-669.
26. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y). 2007;3:112-122. (Pubitemid 46712476)
27. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet. 1998;352:1187-1189. (Pubitemid 28458534)
28. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut. 2001;48:14-19. (Pubitemid 32042636)
29. Caldarella MP, Serra J, Azpiroz F, Malagelada JR. Prokinetic effects in patients with intestinal gas retention. Gastroenterology. 2002;122:1748-1755. (Pubitemid 34651417)
30. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology. 1987;92:1885-1893. (Pubitemid 17072237)
31. Kellow JE, Phillips SF, Miller LJ, Zinsmeister AR. Dysmotility of the small intestine in irritable bowel syndrome. Gut. 1988;29:1236-1243.
32. Galati JS, McKee DP, Quigley EM. Response to intraluminal gas in irritable bowel syndrome. Motility versus perception. Dig Dis Sci. 1995;40:1381-1387.
33. Hernando-Harder AC, Serra J, Azpiroz F, et al. Colonic responses to gas loads in subgroups of patients with abdominal bloating. Am J Gastroenterol. 2010;105:876-882.
34. Salvioli B, Serra J, Azpiroz F, et al. Origin of gas retention and symptoms in patients with bloating. Gastroenterology. 2005;128:574-579. (Pubitemid 40585358)
35. Salvioli B, Serra J, Azpiroz F, Malagelada JR. Impaired small bowel gas propulsion in patients with bloating during intestinal lipid infusion. Am J Gastroenterol. 2006;101:1853-1857. (Pubitemid 44166597)
36. Serra J, Azpiroz F, Malagelada JR. Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation. Am J Physiol Gastrointest Liver Physiol. 2001;281:G138-G143.
37. Cann PA, Read NW, Brown C, Hobson N, Holdsworth CD. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut. 1983;24:405-411. (Pubitemid 13089484)
38. Shim L, Prott G, Hansen RD, Simmons LE, Kellow JE, Malcolm A. Prolonged balloon expulsion is predictive of abdominal distension in bloating. Am J Gastroenterol. 2010;105:883-887.
39. Passos MC, Serra J, Azpiroz F, Tremolaterra F, Malagelada JR. Impaired reflex control of intestinal gas transit in patients with abdominal bloating. Gut. 2005;54:344-348. (Pubitemid 40299089)
40. Alvarez W. Hysterical type of nongaseous abdominal bloating. Arch Intern Med. 1949;84:217-245.
41. Tremolaterra F, Villoria A, Azpiroz F, Serra J, Aguadé S, Malagelada JR. Impaired viscerosomatic reflexes and abdominal-wall dystony associated with bloating. Gastroenterology. 2006;130:1062-1068.
42. Villoria A, Azpiroz F, Soldevilla A, Perez F, Malagelada JR. Abdominal accommodation: a coordinated adaptation of the abdominal wall to its content. Am J Gastroenterol. 2008;103:2807-2815.
43. Accarino A, Perez F, Azpiroz F, Quiroga S, Malagelada JR. Abdominal distention results from caudo-ventral redistribution of contents. Gastroenterology. 2009;136:1544-1551.
44. Maxton DG, Martin DF, Whorwell PJ, Godfrey M. Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms. Gut. 1991;32:662-664.
45. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995;109:40-52.
46. Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology. 2002;122:1771-1777. (Pubitemid 34651420)
47. Agrawal A, Houghton LA, Lea R, et al. Bloating and distention in irritable bowel syndrome: the role of visceral sensation. Gastroenterology. 2008;134:1882-1889. (Pubitemid 351783263)
48. Chang L, Lee OY, Naliboff B, Schmulson M, Mayer EA. Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. Am J Gastroenterol. 2001;96:3341-3347. (Pubitemid 34016658)
49. Taub E, Cuevas JL, Cook EW 3rd, Crowell M, Whitehead WE. Irritable bowel syndrome defined by factor analysis. Gender and race comparisons. Dig Dis Sci. 1995;40:2647-2655. (Pubitemid 26032355)
50. Cain KC, Headstrom P, Jarrett ME, et al. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:124-132. (Pubitemid 43381719)
51. Hasler WL, Wilson LA, Parkman HP, et al. Bloating in gastroparesis: severity, impact, and associated factors. Am J Gastroenterol. 2011;106:1492-1502.
52. Koloski NA, Talley NJ, Boyce PM. Does psychological distress modulate functional gastrointestinal symptoms and health care seeking? A prospective, community cohort study. Am J Gastroenterol. 2003;98:789-797. (Pubitemid 36576303)
53. Song JY, Merskey H, Sullivan S, Noh S. Anxiety and depression in patients with abdominal bloating. Can J Psychiatry. 1993;38:475-479. (Pubitemid 23337848)
54. Park HJ, Jarrett M, Cain K, Heitkemper M. Psychological distress and GI symptoms are related to severity of bloating in women with irritable bowel syndrome. Res Nurs Health. 2008;31:98-107.
55. Jones MP, Sharp LK, Crowell MD. Psychosocial correlates of symptoms in functional dyspepsia. Clin Gastroenterol Hepatol. 2005;3:521-528. (Pubitemid 40824744)
56. Accarino A, Perez F, Azpiroz F, Quiroga S, Malagelada JR. Intestinal gas and bloating: effect of prokinetic stimulation. Am J Gastroenterol. 2008;103:2036-2042.
57. Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33:1059-1067.
58. Lappinga PJ, Abraham SC, Murray JA, Vetter EA, Patel R, Wu TT. Small intestinal bacterial overgrowth: histopathologic features and clinical correlates in an underrecognized entity. Arch Pathol Lab Med. 2010;134:264-270.
59. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol. 2005;100:1566-1570. (Pubitemid 41032365)
60. Corazza G, Strocchi A, Sorge M, Bentai G, Gasbarrini G. Prevalence and consistency of low breath H2 excretion following lactulose ingestion. Possible implications for the clinical use of the H2 breath test. Dig Dis Sci. 1993;38:2010-2016. (Pubitemid 23336563)
61. Valentin T, Leitner E, Rohn A, et al. Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J Infect. 2011;62:34-38.
62. Pimentel M, Lembo A, Chey W, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.
63. Choi YK, Kraft N, Zimmerman B, Jackson M, Rao SS. Fructose intolerance in IBS and utility of fructose-restricted diet. J Clin Gastroenterol. 2008;42: 233-238. (Pubitemid 351301486)
64. Barrett JS, Gibson PR. Clinical ramifications of malabsorption of fructose and other short-chain carbohydrates. Practical Gastroenterol. 2007;31:51-65. (Pubitemid 47326716)
65. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008;6:765-771.
66. Goldstein R, Braverman D, Stankiewicz H. Carbohydrate malabsorption and the effect of dietary restriction on symptoms of irritable bowel syndrome and functional bowel complaints. Isr Med Assoc J. 2000;2:583-587.
67. Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. 2011;106:508-514.
68. Villoria A, Serra J, Azpiroz F, Malagelada JR. Physical activity and intestinal gas clearance in patients with bloating. Am J Gastroenterol. 2006;101:2552-2557. (Pubitemid 44665252)
69. Dainese R, Serra J, Azpiroz F, Malagelada JR. Influence of body posture on intestinal transit of gas. Gut. 2003;52:971-974. (Pubitemid 36765288)
70. Suarez FL, Furne J, Springfield J, Levitt MD. Failure of activated charcoal to reduce the release of gases produced by the colonic flora. Am J Gastroenterol. 1999;94:208-212. (Pubitemid 29063470)
71. Bernstein JE, Kasich AM. A double-blind trial of simethicone in functional disease of the upper gastrointestinal tract. J Clin Pharmacol. 1974;14:617-623.
72. Ganiats TG, Norcross WA, Halverson AL, Burford PA, Palinkas LA. Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. J Fam Pract. 1994;39:441-445. (Pubitemid 24346733)
73. Ringel-Kulka T, Palsson OS, Maier D, et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol. 2011;45:518-525.
74. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541-551. (Pubitemid 40585355)
75. Whorwell PJ, Altringer L, More J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581-1590. (Pubitemid 43980633)
76. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:895-904. (Pubitemid 36459602)
77. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17:687-696. (Pubitemid 41400717)
78. Guandalini S, Chiaro A, Romano C, et al. Efficacy of the probiotic VSL#3 in children with irritable bowel syndrome. An international, randomized, placebocontrolled, double-blind, cross-over trial. Am J Gastroenterol. 2008;103:A1342.
79. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557-563. (Pubitemid 46780934)
80. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-333. (Pubitemid 43381675)
81. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58:367-378.
82. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125:19-31. (Pubitemid 36799103)
83. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15:355-361. (Pubitemid 32187557)
84. Cash BD, Lacy BE. Systematic review: FDA-approved prescription medications for adults with constipation. Gastroenterol Hepatol (N Y). 2006;2:736-749. (Pubitemid 44851258)
85. DiPalma JA, Cleveland MB, McGoan J, Herrera JL. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South Med J. 2007;100:1085-1090. (Pubitemid 350071173)
86. Chung JM. Cisapride in chronic dyspepsia: results of a double-blind, placebocontrolled trial. Scand J Gastroenterol Suppl. 1993;195:11-14. (Pubitemid 23135137)
87. Kellow JE, Cowan H, Shuter B, et al. Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther. 1995;9:153-160.
88. Champion MC, MacCannell KL, Thomson AB, et al. A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group. Can J Gastroenterol. 1997;11:127-134. (Pubitemid 27146011)
89. Farup PG, Hovdenak N, Wetterhus S, Lange OJ, Hovde O, Trondstad R. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol. 1998;33:128-131. (Pubitemid 28098225)
90. Parkman HP, Hasler WL, Fisher RS; American Gastroenterological Association. American Gastroenterological Association medical position statement: diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1589-1591. (Pubitemid 39457782)
91. Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol. 1997;92:976-980. (Pubitemid 27237588)
92. Lacy BE, Cash BD. A 32-year-old woman with chronic abdominal pain. JAMA. 2008;299:555-565. (Pubitemid 351214253)
93. Johnson AG. Controlled trial of metoclopramide in the treatment of flatulent dyspepsia. Br Med J. 1971;2:25-26.
94. Lacy BE, Yu S. Tegaserod: a new 5-HT4 agonist. J Clin Gastroenterol. 2002;34:27-33. (Pubitemid 34038476)
95. Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15:1655-1666. (Pubitemid 32912410)
96. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002;16:1877-1888.
97. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut. 2003;52:671-676. (Pubitemid 36528868)
98. Nyhlin H, Bang C, Elsborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol. 2004;39:119-126. (Pubitemid 38253623)
99. Drossman DA, Chey WD, Panas R, et al. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two twelve-week, randomized, placebo-controlled, double blind trials. Gastroenterology. 2007;132:2586-2587.
100. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138:886-895.
101. Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome. Gastroenterology. 2010;139:1877-1886.